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Abstract: The enzyme NQO1 is a potential target for selective cancer therapy due to 
its overexpression in certain hypoxic tumors. A series of prodrugs possessing a variety 
of cytotoxic diterpenoids (oridonin and its analogues) as the leaving groups activated 
by NQO1 were synthesized by functionalization of 3-(hydroxymethyl)indolequinone, 
which is a good substrate of NQO1. The target compounds (29a-m) exhibited 
relatively higher antiproliferative activities against NQO1-rich human colon 
carcinoma cells (HT-29) and human lung carcinoma (A549) cells (IC50 = 0.263-2.904 
µM), while NQO1-defficient lung adenosquamous carcinoma cells (H596) were less 
sensitive to these compounds, among which, compound 29h exhibited the most potent 
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antiproliferative activity against both A549 and HT-29 cells, with IC50 values of 0.386 
and 0.263 µM, respectively. Further HPLC and docking studies demonstrated that 29h 
is a good substrate of NQO1. Moreover, the investigation of anticancer mechanism 
showed that the representative compound 29h affected cell cycle and induced NQO1 
dependent apoptosis through an oxidative stress triggered mitochondria-related 
pathway in A549 cells. Besides, the antitumor activity of 29h was also verified in a 
liver cancer xenograft mouse model. Biological evaluation of these compounds 
concludes that there is a strong correlation between NQO1 enzyme and induction of 
cancer cell death. Thus, this suggests that some of the target compounds activated by 
NQO1 are novel prodrug candidates potential for selective anticancer therapy. 
  
Keywords: NQO1; Oridonin; indolequinone; hypoxia-selective; antitumor 
 
1. Introduction 
Nonselective toxicity is a major factor that contributes to poor prognosis for cancer 
patients. One of the approaches to improve therapeutic effectiveness and decrease 
systemic side effects is design of targeted anticancer prodrugs for tumor site-specific 
activation [1]. A number of prodrug designs have been proposed to meet these 
requirements by taking advantages of low extracellular pH [2], elevated enzymes in 
tumor tissues [3], hypoxic environment inside the tumors [4], and so on [5]. Hypoxia 
is a common feature of most solid tumors, tissue hypoxia due to inadequate blood 
supply and rapid tumor growth will induce cancer cells resistant to radiotherapy and 
to many chemotherapeutic strategies [6]. However, tumor hypoxia also distinguishes 
tumor cells from normal cells, thus providing a unique strategy for selective cancer 
therapy [7]. Hypoxic cells prevalent in solid tumors could be selectively targeted by 
bio-reductive compounds whose activation is limited to hypoxic tumor regions thus 
minimizing the systemic side effects [8]. Hypoxia-activated prodrugs are activated by 
biotransformation following reductive metabolism by endogenous human cellular 
oxidoreductases [9].  
Although a variety of oxidoreductases are known to be involved in prodrug 
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reduction, two-electron oxidoreductases NAD(P)H:quinone oxidoreductase (NQO1) 
is shown to be the most extensively researched [10]. NQO1 (E.C. 1.6.99.2, reduced 
nicotinamide adenine dinucleotide phosphate, also known as DT-diaphorase, DTD) is 
an obligate two electron quinone reductase. This flavoenzyme can utilize either 
NADH or NADPH to catalyze the reduction of various bio-reductive prodrugs [11]. 
NQO1 has received considerable attention in recent years for prodrug development, 
due to the fact that this enzyme is overexpressed in various types of tumors as 
compared with the paired normal tissue, making it an interesting target enzyme. 
Elevated levels of NQO1 in human tissues have been observed in primary tumors 
from lung (12- to 18-fold), liver (4- to 19-fold), colon (3- to 4-fold), and breast (3-fold) 
compared with normal tissue [12]. Therefore, NQO1 becomes an attractive target for 
enzyme-directed anticancer prodrugs designed for reductive activation. 
Several classes of bio-reductive compounds that can undergo enzymatic reduction 
to active species have been developed [13-15]. Quinone is the structural moiety 
commonly associated with reductive activation which can be easily reduced by 
various reductive enzymes to hydroquinones[16]. Quinone is present in many 
bio-reductive compounds, such as mitomycin C (1), a clinically used antitumor 
antibiotic [17], and EO9 (2) that shows improved properties over mitomycin C [18], 
as well as other quinone-containing compounds (Figure 1) [19-20]. 
 
Figure 1. Chemical structures of antitumor quinones. 
 
The indolequinone nucleus is the most common quinone which is a good substrate 
of NQO1 and can be activated through an obligate and non-reversible two-electron 
reduction. Recently, structure-activity relationship (SAR) analysis of the 
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indolequinone moiety and the molecular features relating to substrate specificity for 
human NQO1 has been examined [21-23]. Evidence indicates that substitution with a 
potential leaving group at the 3-position of the indolequinone moiety is a viable 
means for bio-reductive drug delivery [24]. Figure 2 shows a proposed mechanism for 
the release of drugs following reduction of the indolequinone prodrug 5. When 5 is 
reduced by two electrons to dihydroxyindole 6 in the presence of NQO1, the 
electron-density at the indole nitrogen increases markedly, triggering expulsion of the 
leaving group 7. This expulsion generates an alkenyliminium electrophile 8, which is 
a potential electrophile capable of DNA-alkylation or other cellular-damaging events 
contributing to the cytotoxicity to tumor cells [25]. This reduction is often inhibited in 
the presence of oxygen, thus increasing the specificity for hypoxic solid tumors. 
Interestingly, if the leaving group 7 is a bioactive group, thus they may have 
secondary biological effects due to the eliminated molecule 7 [26-28]. As shown in 
Figure 2, there are two mechanisms through which indolequinone-based prodrugs can 
induce cytotoxicity. Firstly, the indolequinone structure itself can be converted to a 
reactive, cytotoxic species by reduction to a hydroquinone. Secondly, the 
indolequinone moiety can be used to form a prodrug that selectively releases other 
cytotoxic agents to hypoxic tissues. Thus, design and synthesis of NQO1-activated 
indolequinone prodrugs by functionalization at the (indol-3-yl)methyl position with a 
variety of cytotoxic leaving groups have become an interesting area to develop 
targeted anticancer prodrugs. 
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Figure 2. Schematic illustration for activation of NQO1-targeted prodrugs upon 
hypoxic irradiation. 
 
Natural product oridonin (10), an ent-kaurene diterpenoid extracted from Radosia 
Rubescens, was firstly identified in 1967 as an antitumor agent [29-30]. Numerous 
researches have shown that oridonin has certain antitumor effects on human breast 
cancer, gallbladder cancer, leukemia, gastric cancer, human cervical carcinoma, 
hepatocellular carcinoma and other tumors [31]. In our previous studies, oridonin and 
its semi-synthesized analogues exhibited safe, unique, and extensive antitumor 
activities [32-34]. In the present study, a series of reductively triggered novel prodrugs 
were designed by substitution at the 3-position of the indolequinone nucleus with 
cytotoxic diterpenoids oridonin or its analogues. The active drug oridonin or its 
analogues were subsquently released under bio-reductive transformation by NQO1 
which is overexpressed in tumor tissues. This design is expected to enhance drug 
specificity toward tumor cells and thus reduce side effects. 
Herein, we report the design, synthesis and preliminary drug release study of 
NQO1-targeted oridonin prodrugs possessing indolequinone moiety for 
bio-reductively triggered drug release. 
 
2. Results and discussion 
2.1. Synthesis of NQO1-targeted oridonin prodrugs 
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The conversion of kaurene-type oridonin to 6,7-seco-kaurene-type compounds 
12-13 was achieved by periodate. As shown in Scheme 1, treatment of 10 with sodium 
periodate in water gave 12 in 98% yield. Subsequent oxidation of 12 with Jones 
reagent at room temperature afforded lactone 13 in 90% yield. According to our 
previous report, treatment of 10 with 2,2-dimethoxypropane in the presence of TsOH 
in acetone provided ketal 14 in 95% yield [35]. Compound 14 upon reaction with 
Ac2O/DMAP/TEA led to acetylated compound 15 in the yield of 92%. Then, 
deprotection of 15 with 10% HCl/THF gave the corresponding alcohol 16 in almost 
quantitative yield. Besides, the 1-hydroxy of compound 14 was selectively activated 
by MsCl, which was subsequently subjected to an elimination reaction in the presence 
of Li2CO3 and LiBr in DMF at 110 oC to provide 1-ene 19 in 85% yield. Removal of 
the acetonide group in 17 and 19 with 10 % HCl aqueous solution offered 18 and 20 
in yield of 93 % and 95%, respectively. 
 
Scheme 1. Synthesis of oridonin analogues 11-20a 
  
aReagents and conditions: (a) Jones’ reagent, acetone, 0 oC, 15 min, 94%; (b) NaIO4, 
H2O, rt, 24 h, 98%; (c) Jones’ reagent, acetone, rt, 15 min, 90%; (d) 
2,2-Dimethoxypropane, acetone, TsOH, 56 oC, 30 min, 95%; (e) Ac2O, TEA, DMAP, 
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rt, 2 h, 92%; (f) 10% HCl, THF, rt, 30 min, 97%; (g) MsCl; TEA, 0 oC, 2 h, 88%; (h) 
10% HCl, THF, rt, 20 min, 93%. (i) LiCO3, LiBr, THF, 110 oC, 1 h, 85%; (j) 10% HCl, 
THF, rt, 30 min, 95%. 
 
The synthesis of indolequinone skeleton was carried out as depicted in Scheme 2 
starting from 5-methoxyindole (21) [36]. Briefly, formylation of 21 produced 22 in 
almost quantitative yield, methylation of 22 using methyl iodide in the presence of 
sodium hydride gave 23 in 95% yield. Nitration of 23 using conc. HNO3 in acetic acid 
gave 24 in 73% yield. Reduction of the nitro group of 24 using Sn/HCl produced the 
amine 25 followed by oxidation using Fremy’s salt to gave 26, which was 
subsequently reduced using NaBH4 to afford 27 in 70% yield. In order to install 
oridonin or its analogues at the 10-position of indolequinone, we converted the 
hydroxyl group of 27 into the carboxyl function to give compounds 28a-b using 
succinic anhydride or glutaric anhydride. The target compounds 29a-n were obtained 
by coupling 28a-b with oridonin or its analogues through the condenstation reaction 
in the presence of EDCI and DMAP with 48-92% yields.  
 
Scheme 2. Synthesis of NQO1-targeted prodrug candidates 29a-na 
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aReagents and conditions: (a) POCl3, DMF, 0 °C to rt, 2 h, 90%; (b) NaH, MeI, DMF, 
rt, 30 min, 95%; (c) HNO3, AcOH, 10-15 °C, 73%; (d) Sn, HCl, MeOH, rt, 57%; (e) 
Fremy’s salt, acetone, PBS pH=6.4, 3 h, 45%; (f) NaBH4, MeOH, 10 min, 70%; (g) 
Anhydride, DMAP, DCM, rt, 12-24 h, 55%-80%; (h) EDCI, DMAP, rt, 0.5-24 h, 
48-92%. 
 
2.2. Effect of prodrugs on cancer cell growth 
To assess the extent to which NQO1 contributes to the cytotoxicity of these 
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compounds, MTT assay was performed in three different tumor cell lines: human 
colon carcinoma cells (HT-29), human lung carcinoma cells (A549), and human lung 
adenosquamous carcinoma cells (H596). HT-29 and A549 cells have a high level of 
NQO1 activity, while H596 cells have a relative low level of NQO1 activity. Taxol 
was used as a positive control in this study. As shown in Table 1, most target 
compounds exhibited relatively higher anticancer activities against NQO1-rich A549 
and HT-29 cell lines, with IC50 values ranging from 0.216 to 2.904 µM, whereas 
NQO1-defficient H596 cells were markedly less sensitive to these compounds. 
Selectivity ratios defined as IC50(H596)/IC50(A549) were generally > 1, except for 
compound 29a, indicating that these compounds were more cytotoxic to the 
NQO1-rich cells due to activation by NQO1 enzyme. As compared to parent oridonin, 
NQO1 targeted prodrugs showed higher antiproliferative activities against all three 
cancer cell lines. Compounds 29h and 29f were at least 17 times more active than 
parent oridonin (1) against NQO1-rich cells. The difference was most notable in A549 
cells, where 29h was 59-fold more potent than oridonin. Among the tested 
compounds, compound 29h exhibited the strongest antiproliferative activity against 
both A549 and HT-29 cells, with IC50 values of 0.386 and 0.263 µM, respectively, 
which deserves further investigations. 
 
Table 1. IC50 values (µM) of final and reference compounds on inhibiting 
proliferation of human cancer and normal cellsa  
Compounds 
IC50 (µM)b 
Selectivityc HT-29 
(NQO1+) 
A549 
(NQO1+) 
H596 
(NQO1-) 
LO2 
Taxol 0.025 0.023 0.035 0.002 1.52 
1 7.099 15.525 11.969 25.023 0.77 
29a 1.112 2.904 1.699 7.907 0.59 
29b 1.299 0.458 1.681 8.232 3.67 
29c 0.755 1.077 1.650 5.539 1.53 
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29d 0.693 0.363 1.062 4.124 2.93 
29e 1.119 2.596 3.747 4.893 1.44  
29f 0.399 0.286 1.350 1.276 4.72 
29g 0.344 0.524 0.890 1.096 1.70 
29h 0.386 0.263 1.505 2.113 5.72 
29i 1.054 0.689 1.863 7.722 2.70 
29j 0.462 0.403 0.900 2.044 2.23 
29k 1.715 2.067 2.631 6.087 1.27 
29l 0.754 0.405 2.001 3.269 4.94 
29m 0.527 0.729 0.782 1.590 1.07 
29n 1.114 0.373 1.746 7.458 4.68 
aMTT methods, cells were incubated with indicated compounds for 72h, the values are the means 
of three independent experiments; bHT-29, Human colon carcinoma cells (High NQO1 activity, 
NQO1+); A549, Human lung carcinoma cells (High NQO1 activity, NQO1+); H596, Human lung 
carcinoma cells (No NQO1 activity, NQO1-); LO2, Human normal liver cells; cSelectivity = 
IC50(H596)/ IC50(A549). 
 
Consequently we measured the antiproliferative activities of three potent 
representative compounds 29f, 29h, 29n in the presence of dicoumarol (DIC, 10 mM), 
an effective NQO1 inhibitor that blocks the catalytic efficiency of the enzyme by 
interacting with the NAD(P)H-binding site of the oxidized enzyme form. As shown in 
Figure 3A, the co-incubation with DIC led to lower sensitivity of A549 cells to 
compounds 29f, 29h, 29n, and increasing IC50 values up to 7.5-, 4.5- and 5.9- fold, 
respectively, which implies that they might be partially influenced by their 
NQO1-catalyzed bio-reductive activation. 
Furthermore, we found the synergic effect of compound 29h in both A549 and 
H596 cells. As shown in Figure 3B, compound 29h contains an oridonin analogue 
(compound 13) and indolequinone (27) moieties, the IC50 values of 29h for A549 
(0.263 µM) and H596 cells (0.386 µM) were significantly less than that of the 
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equimolar combination of 13 and 27 (IC50 = 6.143 and 5.823 µM), respectively. These 
results suggest that the anti-tumor activity of 29h may be attributed to the synergic 
effects of oridonin and indolequinone moieties as well as hypoxia-selective activation 
in cancer cells. 
 
 
Figure 3. NQO1 contributes to the cytotoxicity of these newly designed 
indolequinone prodrugs. (A) Compounds induced cytotoxicity is NQO1 dependent. 
A549 cells were pretreated with 10 mM DIC for 30 min, then incubated with 
indicated compounds, DIC (dicoumarin), NQO1 inhibitor; (B) Comparison of 
anticancer activity of compound 29h with that of equimolar mixture of 13 and 27.  
MTT methods, cells were incubated with indicated compounds for 72h, (means ± SD, 
n=3). 
 
2.3. Compound 29h is a good substrate of NQO1 
To assess the efficacy of these newly synthesized compounds as substrates for 
NQO1, HPLC analysis was used to monitor the decomposition of 29h in the presence 
or absence of NQO1 in pH 7.4 buffer. Upon reduction with NQO1, the electron 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
density at the indole nitrogen increases drastically, triggering expulsion of the leaving 
group in a reverse-Michael-like process, releasing the drug at the 3-position of the 
indolequinone nuclear. As shown in Figure 4, within 40 min, a significant amount of 
29h was decomposed in the presence of NQO1, and in 12 h, nearly 70% of the 
compound was consumed. However, during the same time period, in the absence of 
NQO1, 29h remained stable in pH 7.4 buffer suggesting NQO1 could mediate 
hypoxic induced, enzyme-directed bio-reductive drug delivery.  
Moreover, docking study of representative compound 29h was further performed to 
observe whether this prodrug is a good substrate of NQO1. The molecular operating 
environment (MOE) was used to analyse the binding mode of 29h with NQO1, Figure 
4B showed the possible docking conformation for 29h with NQO1. It can be clearly 
seen that indolequinone moiety binds with the residues of the NQO1 active site and 
flavin adenine dinucleotide (FAD) which is required for NQO1 catalytic activity 
(Figure 4B). The leaving group 13 is left outside the substrate binding pocket, 
suggesting that the interaction of indolequinone with NQO1 active site is not affected 
by the introduction of oridonin or its analogues to indolequinone. This binding mode 
was consistent with the HPLC data indicating that 29h is a good substrate for NQO1. 
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Figure 4. These newly synthesized prodrugs are good substrates of NQO1. (A) 
Decomposition profiles of 29h in the presence and absence of NQO1 were determined 
by HPLC analysis. (B) Docked conformation of compound 29h into active site of 
NQO1. The interaction mode was obtained through molecular docking (PDB id: 1h29) 
and depicted using PyMOL. FAD is expressed in magenta and 29h is represented as 
stick model, nitrogen atoms are colored in blue, oxygen atoms are colored in red, and 
carbon atoms are colored in cyan. Hydrogen bonds are represented by dashed yellow 
lines along with their distances. 
 
2.4. Compound 29h induces NQO1 dependent apoptotic cell death 
To further investigate the effect of 29h on cell proliferation, Hoechst 33342 staining 
was used to assess 29h-dependent changes in cell morphology. Both A549 and H596 
cells treated with 29h for 36 h displayed changed morphologies, over 12.6% of the 
H596 cells exhibited chromatin condensation upon 0.5 µM of 29h treatment, 
indicating the induction of apoptosis (Figure 5A). However, chromatin condensation 
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was more obvious on A549 cells after treatment with 0.5 µM 29h, approximately 30% 
cells exhibited changed morphologies. Furthermore TUNEL assays were performed to 
confirm that 29h induced cell death is due to the induction of NQO1 dependent 
apoptosis. As shown in Figure 5B, 29h induced a concentration dependent apoptosis 
in A549 cells and the TUNEL positive cells reached over 18.5% upon 0.5 µM of 29h 
treatment, whereas the TUNEL positive cells detected from H596 cells upon 29h 
treatment is of no difference from control treatment at this concentration. The results 
of TUNEL assays are in complete agreement with those from MTT based cytotoxicity 
studies, strongly suggesting that 29h induces an NQO1 dependent apoptotic cell death 
in A549 cells.  
 
Figure 5. Evidence shows that compound 29h induces apoptosis. (A) Cell 
morphological alterations and nuclear changes associated with A549 and H596 cells 
after 29h treatment were assessed by staining with Hoechst 33342 and visualized by 
fluorescence microscopy. *** p < 0.001 compared between A549 and H596 groups. 
(B) TUNEL assay was used to identify apoptosis. Histograms display the percentage 
of apoptotic cells. Data were represented as mean ± SD of three independent 
experiments. *** p < 0.001 vs control group. 
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2.5. The role of ROS generation and mitochondrial membrane depolarization in 
29h-induced cell apoptosis 
Cellular reactive oxygen species (ROS) generation can significantly impact the 
effects of various anticancer agents on tumor cell apoptosis. We have found that 29h 
was reduced by NQO1 to induce the apoptosis in A549 cells. In order to monitor 
intracellular ROS levels in the presence and absence of 29h, DCF staining was 
applied to detect 29h induced ROS formation. As shown in Figure 6A, DCF staining 
data displayed that 29h induced excessive ROS formation in A549 cells but not in 
H596, and 29h treated A549 cells had significantly higher levels of ROS than that in 
control cells. The above results indicated that ROS produced from NQO1 
bio-activation is an important mediator on 29h induced apoptotic cell death. ROS are 
considered to play an important role in apoptosis in various types of cells, and 
mitochondrial membrane depolarization is associated with mitochondrial production 
of ROS, therefore we measured the mitochondrial membrane potential (MMP) in both 
A549 and H596 cells with fluorescent probe JC-1. A549 cells were incubated with 
different concentrations (0, 0.25, 0.5, 1 µM) of 29h for 48 h prior to staining with the 
JC-1, the number of cells with collapsed mitochondrial membrane potentials in 
different groups were determined by flow cytometry analysis, yielding 4.6%, 23.4%, 
31.4%, and 46.3% apoptotic cells, respectively.  
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Figure 6. The depolarization of mitochondrial membrane potential and accumulation 
of ROS production induced by 29h are required for cell apoptosis. (A) Effect of 29h 
on ROS generation. The generation of ROS was measured by using the 
ROS-detecting fluorescent dye DCF- A in combination with FACScan flow 
cytometry. The corresponding histograms of FACScan flow cytometry is shown; (B) 
Effect of compound 29h on the mitochondrial membrane potentials of A549 cells. 
A549 cells were incubated with the indicated concentrations of compound 29h for 48 
h, cells were then collected and stained with JC-1, followed by flow cytometric 
analysis. 
 
2.6. Compound 29h induces cell cycle arrest at G2/M phase  
Most of the antitumor agents inhibit cell proliferation through induction of cell 
cycle arrest [37]. To determine whether the suppression of the cell growth by 29h was 
caused by a cell-cycle effect, DNA-based cell cycle analysis was performed using 
flow cytometry. As illustrated in Figure 7, compound 29h influenced cell cycle 
progression at sub-micromolar concentrations and caused blockage of the cell cycle at 
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G2/M phase. Compared with the control cells treated with DMSO, when A549 cells 
were treated with increasing concentrations of 29h (0.125, 0.25, 0.5 µM), the 
percentage of cells in the G2/M phase increased from 12.65 % to 26.57 %, and the 
percentages of cells in S and G1 phases decreased concomitantly. The above results 
suggested that these prodrugs may inhibit cancer cell proliferation through cell cycle 
arrest at G2/M phase. 
 
 
Figure 7. Compound 29h induces G2/M phase arrest in the A549 cells. A549 cells 
were treated with DMSO and varying concentrations of 29h (0.125, 0.25, 0.5 µM) for 
48 h, cells were harvested and stained with PI, then analyzed by flow cytometry. The 
percentage of cells at different phases of cell cycle was determined by ModFit 4.1, 
histograms display the percentage of cell cycle distribution. 
 
2.7. Compound 29h regulates apoptotic related proteins 
  The intrinsic and extrinsic pathways that lead to the induction of apoptosis are 
known to activate a series of proteases known as caspases [38]. To explore the 
signalling mechanism of 29h-induced apoptosis, we examined the expression of the 
apoptosis-related proteins including caspase-3, -8, -9, and cytochrome C. As shown in 
Figure 8A, A549 cells treated with 29h had increased levels of the cleaved active 
forms of caspase-3, -8, -9, and cytochrome C in a dose-dependent manner, indicating 
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that 29h activated the caspase cascade. 
The Bcl-2 family has been identified as essential proteins in controlling the 
mitochondrial pathway. This family includes pro-apoptotic proteins (e.g., Bax, Bad) 
and anti-apoptotic proteins (e.g., Bcl-2, Bcl-xL), the balance between these two 
groups determines the fate of cells [39]. Bax can act on the mitochondria to induce the 
mitochondrial permeability transition, resulting in the release of some components, 
including cytochrome C. To confirm whether such a mechanism is involved in 
apoptosis induced by 29h, the expression of Bax and Bcl-xl was examined by Western 
Blotting analysis. As shown in Figure 8B, the expression of Bax in A549 cells began 
to increase after the treatment of 29h with increasing concentrations for 48 h, while 
the Bcl-xl expression markedly decreased at concentrations of 0.25 µM and above. 
While a similar trend was observed in H596 cells, however, such effect was minimal. 
 
 
Figure 8. Effects of compound 29h on the apoptosis related proteins. A549 and H596 
cells were treated with various concentrations of 29h (0, 0.25, 0.5, 1.0 µM) for 48h, 
the expressions of caspase-3, caspase-8, caspase-9, cytochrome C, Bcl-2, and Bax 
were determined by Western Blotting using specific antibodies, β-actin was used as 
internal control.  
 
2.8. In vivo antitumor activity of compound 29h  
To evaluate the in vivo antitumor activity of 29h, liver cancer xenograft in mice 
was established by subcutaneous inoculation of H22 cells into the right flank of mice. 
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As shown in Figure 9A, compound 29h caused a remarkable reduction in tumor 
growth, and reached a 64.3% reduction by the end of the observation period compared 
with administration of vehicle only. It is interesting to note that the effect on tumor 
volume reduction by 29h was much better than that of oridonin, which caused a 50.8% 
of reduction at day 18. During the whole treatment period, no significant weight 
changes in the treated animals were observed (Figure 9D), suggesting that 29h has 
minimal toxicity. 
 
 
Figure 9. 29h exerted potent antitumor activity against liver cancer xenograft growth 
in vivo. (a) H22 cells were subcutaneously inoculated into the right flank of mice. The 
mice were randomly divided into four groups with 8 mice in each group and treated 
intravenously with 29h (20 mg/kg), oridonin (20 mg/kg), cyclophosphamide (20 
mg/kg), and DMSO (dissolved in sodium chloride as control) every day for 18 days 
and the figure showed the average measured tumor volumes; (b) 29h treatment 
resulted in significantly lower tumor weight compared with control, ***P<0.001; (c) 
The resulting tumors were excised from the animals after treatment; (d) Body weight 
changes of mice during treatment. 
 
3. Conclusion 
In this study, a series of hypoxia-selective prodrugs were designed and synthesized 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
by functionalization of the 3-(hydroxymethyl)indolequinone with a variety of leaving 
groups including anticancer diterpenoids oridonin and its analogues at the 
(indol-3-yl)methyl position. The resulting compounds (29a-m) exhibited relatively 
high antitumor activities against NQO1-rich A549 and HT-29 cell lines, and 
compound 29h has been found to be the most potent compound with IC50 values of 
0.386 and 0.263 µM against A549 and HT-29 cells, respectively. A significant 
correlation between NQO1 activation and cytotoxicity was observed by using MTT 
assay, HPLC analysis and docking study, suggesting that indolequinone moiety 
contributes to the increased antiproliferative activities of targeted compounds. 
Moreover, the investigation of anticancer mechanism revealed that the representative 
compound 29h affected cell cycle and induced NQO1 dependent apoptosis through an 
oxidative stress triggered mitochondria-related pathway in A549 cells. Besides, the 
anti-tumor activity of 29h was verified in a liver cancer xenograft mouse model with 
no observable toxicity.   
Overall, these NQO1-targeted oridonin prodrugs possessing indolequinone moiety 
represent a promising class of cytotoxic agents with potential novel therapeutic values. 
All properties including the cancer cell selectivity, potency, and promising in vivo 
activity of compound 29h suggested its outstanding potential as a personalized 
anticancer therapy [40]. 
 
4. Experimental section 
4.1. Materials  
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT), 
5,5′,6,6′-Tetrachloro-1,1′,3,3′-tetraethyl-imidacarbocyanine iodide (JC-1), 
DT-diaphorase enzyme, NADH, FDA, and 2’,7’-Dichlorofluorescein diacetate 
(DCF-DA), were purchased from Sigma Chemical Co. (St. Louis, MO, USA). 
Primary antibodies against caspase-3, caspase-8, caspase-9, Bax, Bcl-xl, cytochrome 
C, β-actin were purchased from Beyotime (Jiangsu, China), and secondary antibodies 
(goat-anti-rabbit or goat-anti-mouse) were purchased from Life Technologies (Grand 
Island, NY, USA). All cell culture reagents including no-essential amino acids (NEAA) 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
and the BCA protein assay kit were purchased from Life Technologies (Grand Island, 
NY, USA). Institute of Cancer Research (ICR) female mice were purchased from 
Shanghai SLAC Laboratory Animals Co. Ltd. (China).  
 
4.2. Cell Lines and Cell Culture 
Human NSCLC cell lines A549 (NQO1+), NCI-H596 (NQO1-) and Human colon 
carcinoma cells HT-29 (NQO1+) were obtained from the American Type Culture 
Collection (ATCC, USA). Cells were grown in RPMI 1640 medium (Life 
Technologies, USA). The media for all cell lines were supplemented with 10% fetal 
bovine serum (Life Technologies, USA), 100 µg/mL streptomycin (Life Technologies, 
USA), and 100 U/mL penicillin (Life Technologies, USA) and maintained at 37°C in 
a humidified atmosphere with 5% CO2.  
 
4.3. Determination of In Vitro Anticancer Activity 
The overall growth level of human cancer cell lines was determined by the MTT 
colorimetric assay. Cells were plated in 96-well plates at a density of 10000 cells/mL 
and incubated at 37 °C in a humidified 5 % CO2 incubator for 24 h prior to the 
experiments. After medium removal, 100 µL of fresh medium containing the test 
compound at different concentrations was added to each well and incubated at 37 °C 
for 72 h, the percentage of DMSO in the medium never exceeded 0.25%. The number 
of living cells after 72 h of culture in the presence (or absence: control) of the various 
compounds is directly proportional to the intensity of the blue, which is quantitatively 
measured by a plate reader at 560 nm. The experiment was performed in 
quadruplicate and repeated 3 times. 
 
4.4. Metabolism of 29h by DT-D 
A 10 mM stock solution of 29h was prepared in DMSO and stock solutions of 4 
mM NADH and 100 µM FAD were prepared in TRIS buffer pH 7.4. The enzyme 
stock solution was prepared by dissolving 1.5 mg of the lyophilized human 
DT-Diaphorase (Sigma, ≥100 units; wherein 1 unit is 1.0 µmole cytochrome C 
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reduced per min/mg) in TRIS buffer pH 7.4 to make a solution of 40 mU/µL. The 
reaction mixture was prepared according the spreadsheet below. The reaction mixtures 
were stirred at 37 oC and were monitored by HPLC analysis carried out on a 
Prominence LC-20AT HPLC system equipped with a column (Agilent eclipse XDB 
C18 5µm, 4.6*250mm). The mobile phase used for elution was a linear gradient 
beginning with 50:50 (v/v) methanol: water at a flow rate of 1 mL/min. 
Entry Conditions H2O Buffer 29h NADH FAD NQO1 
1 Control 80µL 40µL 600µL 40µL 40µL 0 
2 With DTD 40µL 40µL 600µL 40µL 40µL 40µL 
Final 
concentration 
/ / 25 mM 0.15mM 0.2 mM 5.0 mM 2.0mU/µL 
 
4.5. Molecular Modelling of 29h in NQO1 
For docking purposes, the crystallographic coordinates of the human NQO1 was 
obtained from Protein Data Bank, (PDB code 1H69 and resolution 1.86 Å) and the 
structure was edited accordingly to provide a monomer of the protein (A chain) by 
MOE 2014.09. Then compound 29h was constructed using the builder molecule and 
was energy minimized as a MDB file. The receptor was defined as the the monomer 
protein and its FAD cofactor. The active site was defined as being the quinone 
scaffold of the original ligand in its crystal pose in the monomer of 1H69. For these 
experiments, the placement was set as Triangle Matcher, rescoring 1 was London dG, 
refinement was forcefiled, and rescoring 2 was GBVI/WSA dG. Other docking 
parameters were set to default. The best pose was visualized with PyMOL Molecular 
Graphics System version 2.7.  
 
4.6. Hoechst 33342 Staining 
Approximately 5×104 cells/well were planted in six-well plates, and the cells were 
then incubated with 0, 0.125, 0.25, 0.5 µM 29h for 36 h. After incubation, cells were 
washed with PBS, fixed in 4% paraformaldehyde for 30 min and then stained with 20 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
µg/ml Hoechst 33342 for 15 min at room temperature in the dark. Cells were then 
assessed by fluorescence microscopy for morphological changes after 29h treatment. 
 
4.7. TUNEL assay 
Terminal deoxynucleotidyl transferase-mediated Dutpnick end-labeling (TUNEL) 
assay was used for detection of DNA strand breaks. The detection was carried out 
according to the instructions of in situ Apoptosis Detection kit (KGA7025, Beyotime, 
China). Briefly, the cells were rinsed once with PBS and fixed in 3.7% buffered 
formaldehyde at room temperature for 10 min. The fixed cells were pre-treated with 
10% H2O2, and end-labeling was performed with TdT labeling reaction mix at 37 °C 
for 1 h. Nuclei exhibiting DNA fragmentation were visualized by incubation in 
3’,3-diamino benzidine (Sigma) for 10 min. The cells were counter-stained with 
methyl green and observed under light microscopy. The nuclei of apoptotic cells were 
stained dark brown and TUNEL-positive cells were determined with relative 
percentage by randomly counting 100 cells. 
 
4.8. JC-1 Assay to Determine MMP 
The MMP was determined with the dual-emission mitochondrial dye JC-1. After 
treatment with 0, 0.25, 0.5, 1 µM 29h for 36 h, A549 and H596 cells were loaded with 
10 µg/mL JC-1 dye for 30 min at 37 °C and then washed for 5 min in PBS buffer. The 
percentage of cells with healthy or collapsed mitochondrial membrane potentials was 
monitored by flow cytometry analysis with an excitation wavelength of 488 nm and 
an emission wavelength of 530 nm an FC500 cytometer (Beckman Coulter). 
 
4.9. Measurement of Intracellular ROS Generation 
Intracellular ROS production was detected by using the peroxide-sensitive 
fluorescent probe DCF-DA. In brief, after treatment with 0, 0.25, 0.5, 1 µM 29h for 
36 h, A549 and H596 cells were incubated with 10 mM DCF-DA at 37 °C for 15 min. 
The intracellular ROS mediated oxidation of DCF-DA to the fluorescent compound 
2’,7’-dichlorofluorescein (DCF). Then cells were harvested and the pellets were 
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suspended in 1 mL PBS. Samples were analysed at an excitation wave length of 480 
nm and an emission wave length of 525 nm by flow cytometry on an FC500 
cytometer (Beckman Coulter). 
 
4.10. Cell Cycle Analysis 
5×104 cells were seeded into 6-well plates and incubated overnight. Cells were then 
treated with various concentrations of compound 29h for 48 h. The cells were 
harvested, washed with cold PBS and then fixed with 70 % ethanol in PBS at -20 °C 
for 12 h. Subsequently, the cells were re-suspended in PBS containing 100 µg/ml 
RNase and 50 µg/ml PI and incubated at 37 °C for 30 min. Cell cycle distribution of 
nuclear DNA was determined by flow cytometry on an FC500 cytometer (Beckman 
Coulter). 
 
4.11. Western Blot Analysis 
A549 and H596 cells were incubated in the presence of 29h, and after 48 h, were 
collected, centrifuged, and washed two times with ice cold PBS. The pellet was then 
re-suspended in lysis buffer. After the cells were lysed on ice for 20 min, lysates were 
centrifuged at 13000g at 4 °C for 15 min. The protein concentration in the supernatant 
was determined using the BCA protein assay reagents. Equal amounts of protein (20 
µg) were resolved using sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) (8-12 % acrylamide gels) and transferred to PVDF Hybond-P 
membrane. Membranes were blocked for 1 h at room temperature. Membranes were 
then incubated with primary antibodies against caspase-3, caspase-8, caspase-9, Bax, 
Bcl-xl, cytochrome C, β-actin, the membrane being gently rotated overnight at 4°C. 
The bound antibodies were detected using horseradish peroxidase (HRP)-conjugated 
second antibodies and visualized by the enhanced chemiluminescent reagent. 
 
4.12. In vivo tumor xenograft study 
Five-week-old male Institute of Cancer Research (ICR) mice were purchased from 
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Shanghai SLAC Laboratory Animals Co. Ltd. A total of 1×106 H22 cells were 
subcutaneously inoculated into the right flank of ICR mice according to protocols of 
tumor transplant research, to initiate tumor growth. After 7 d of tumor transplantation, 
mice in H22 group was weighted and divided into four groups of eight animals at 
random. The groups with oridonin and 29h were administered intravenously 20 mg/kg 
in a vehicle of 10% DMF/2% poloxamer/88% saline, respectively. The positive 
control group was treated with cyclophosphamide (20 mg/kg) through intravenous 
injection. The negative control group received 0.9% normal saline through 
intravenous injection. All the test compounds were given through injections after 7 d 
of tumor transplantation. Treatment were done at a frequency of intravenous injection 
one dose per day for a total 18 consecutive days. Body weights and tumor volumes 
were measured every 2 days. After the treatments, all of the mice were killed and 
weighed. The following formula was used to determine tumor volumes: tumor volume 
= L×W2/2, where L is the length and W the width. Ratio of inhibition of tumor (%) = 
(1 – average tumor weight of treated group/average tumor weight of control group) 
× 100%. The experimental protocols were evaluated and approved by the Ethics 
Committee of the China Pharmaceutical University. 
 
4.13. Synthesis of target compounds 
Synthetic methods of target compounds and intermediates were reported in 
Supporting Information.   
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Lists of Captions: 
 
Figure 1. Chemical structures of antitumor quinones. 
 
Figure 2. Schematic illustration for activation of NQO1-targeted prodrugs upon 
hypoxic irradiation. 
 
Figure 3. NQO1 contributes to the cytotoxicity of these newly designed 
indolequinone prodrugs. (A) Compounds induced cytotoxicity is NQO1 dependent. 
A549 cells were pretreated with 10 mM DIC for 30 min, then incubated with 
indicated compounds, DIC (dicoumarin), NQO1 inhibitor; (B) Comparison of 
anticancer activity of compound 29h with that of equimolar mixture of 13 and 27.  
MTT methods, cells were incubated with indicated compounds for 72h, (means ± SD, 
n=3). 
 
Figure 4. These newly synthesized prodrugs are good substrates of NQO1. (A) 
Decomposition profiles of 29h in the presence and absence of NQO1 were determined 
by HPLC analysis. (B) Docked conformation of compound 29h into active site of 
NQO1. The interaction mode was obtained through molecular docking (PDB id: 1h29) 
and depicted using PyMOL. FAD is expressed in magenta and 29h is represented as 
stick model, nitrogen atoms are colored in blue, oxygen atoms are colored in red, and 
carbon atoms are colored in cyan. Hydrogen bonds are represented by dashed yellow 
lines along with their distances. 
 
Figure 5. Evidence shows that compound 29h induces apoptosis. (A) Cell 
morphological alterations and nuclear changes associated with A549 and H596 cells 
after 29h treatment were assessed by staining with Hoechst 33342 and visualized by 
fluorescence microscopy. *** p < 0.001 compared between A549 and H596 groups. 
(B) TUNEL assay was used to identify apoptosis. Histograms display the percentage 
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of apoptotic cells. Data were represented as mean ± SD of three independent 
experiments. *** p < 0.001 vs control group. 
 
Figure 6. The depolarization of mitochondrial membrane potential and accumulation 
of ROS production induced by 29h are required for cell apoptosis. (A) Effect of 29h 
on ROS generation. The generation of ROS was measured by using the 
ROS-detecting fluorescent dye DCF-DA in combination with FACScan flow 
cytometry. The corresponding histograms of FACScan flow cytometry is shown; (B) 
Effect of compound 29h on the mitochondrial membrane potentials of A549 cells. 
A549 cells were incubated with the indicated concentrations of compound 29h for 48 
h, cells were then collected and stained with JC-1, followed by flow cytometric 
analysis. 
 
Figure 7. Compound 29h induces G2/M phase arrest in the A549 cells. A549 cells 
were treated with DMSO and varying concentrations of 29h (0.125, 0.25, 0.5 µM) for 
48 h, cells were harvested and stained with PI, then analyzed by flow cytometry. The 
percentage of cells at different phases of cell cycle was determined by ModFit 4.1, 
histograms display the percentage of cell cycle distribution. 
 
Figure 8. Effects of compound 29h on the apoptosis related proteins. A549 and H596 
cells were treated with various concentrations of 29h (0, 0.25, 0.5, 1.0 µM) for 48h, 
the expressions of caspase-3, caspase-8, caspase-9, cytochrome C, Bcl-2, and Bax 
were determined by Western Blotting using specific antibodies, β-actin was used as 
internal control.  
 
Figure 9. 29h exerted potent antitumor activity against liver cancer xenograft growth 
in vivo. (a) H22 cells were subcutaneously inoculated into the right flank of mice. The 
mice were randomly divided into four groups with 8 mice in each group and treated 
intravenously with 29h (20 mg/kg), oridonin (20 mg/kg), cyclophosphamide (20 
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mg/kg), and DMSO (dissolved in sodium chloride as control) every day for 18 days 
and the figure showed the average measured tumor volumes; (b) 29h treatment 
resulted in significantly lower tumor weight compared with control, ***P<0.001; (c) 
The resulting tumors were excised from the animals after treatment; (d) Body weight 
changes of mice during treatment. 
 
Scheme 1. Synthesis of oridonin analogues 11-20a 
 
Scheme 2. Synthesis of NQO1-targeted prodrug candidates 29a-na 
 
Table 1. IC50 values (µM) of final and reference compounds on inhibiting 
proliferation of human cancer and normal cellsa  
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Highlights 
1. NQO1-targeted oridonin prodrugs possessing indolequinone moiety 
were prepared. 
2. They showed relatively higher antineoplastic activities against 
NQO1-rich cancer cells. 
3.  The most potent compond 29h is a good substrate of NQO1. 
4. The anti-tumor activity of 29h was verified in a liver cancer xenograft 
mouse model. 
 
